Journal article

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

JC Tiffen, D Gunatilake, SJ Gallagher, K Gowrishankar, A Heinemann, C Cullinane, K Dutton-Regester, GM Pupo, D Strbenac, JY Yang, J Madore, GJ Mann, NK Hayward, GA McArthur, FV Filipp, P Hersey

Oncotarget | IMPACT JOURNALS LLC | Published : 2015

Abstract

The epigenetic modifier EZH2 is part of the polycomb repressive complex that suppresses gene expression via histone methylation. Activating mutations in EZH2 are found in a subset of melanoma that contributes to disease progression by inactivating tumor suppressor genes. In this study we have targeted EZH2 with a specific inhibitor (GSK126) or depleted EZH2 protein by stable shRNA knockdown. We show that inhibition of EZH2 has potent effects on the growth of both wild-type and EZH2 mutant human melanoma in vitro particularly in cell lines harboring the EZH2Y646 activating mutation. This was associated with cell cycle arrest, reduced proliferative capacity in both 2D and 3D culture systems, a..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Cancer Institute


Funding Acknowledgements

This work is supported by NHMRC program grant 633004; the Melanoma Institute of Australia; Cancer Institute NSW. The MD Anderson RPPA Core Facility is supported by NCI grant no. CA16672. AH is supported by Deutsche Forschungsgemeinschaft (DFG project no: HE 6983/1-1).